Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG13909 in Congenital Adrenal Hyperplasia
NCT05669950Phase 2Recruiting
- Sponsor
- Lundbeck
- Start
- Dec 2022
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of Lu AG13909 in congenital adrenal hyperplasia (CAH), sponsored by Lundbeck. Started Dec 2022; status: recruiting.
02
Drugs
Lu AG13909
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT05669950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669950.